Dr. Ulrich Grau

Independent Biopharma Consultant

Ulrich has over 30 years of experience in the biotechnology and pharmaceutical industries and now advises biotech clients on business strategies, and serves on the Boards of Affimed BV, and i-novion, Inc., a company that he co-founded.

Most recently, Ulrich was Chief Operating Officer at Micromet, a public oncology company with a proprietary bi-specific antibody technology and clinical programs in various tumor types. Micromet was acquired by Amgen in 2012. Between 2006 and 2010, Ulrich was a founder, President and CEO of Lux Biosciences, Inc., a clinical stage ophthalmic company. Previously, he served as President of Research and Development at BASF Pharma/ Knoll where he directed a global R&D organization. The development pipeline included most notably a human antibody directed against TNF (adalimumab, Humira®) for the treatment of rheumatoid arthritis and other autoimmune diseases. BASF Pharma was acquired by Abbott in 2002, and Humira® is today the best-selling pharmaceutical product globally.

For 18 years, Ulrich held positions of increasing responsibility at Hoechst and successor companies, where he last served as senior vice president Global Product Realization of Hoechst Marion Roussel. Insulin Glargine (Lantus®) is based on his inventions at the beginning of his career at Hoechst.

Ulrich received his Ph.D. in chemistry and biochemistry from the University of Stuttgart and spent three years as a post-doctoral fellow at Purdue University in the field of protein crystallography.